Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab versus teriflunomide in relapsing multiple sclerosis
NL-OMON47697Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Feb 2017
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ofatumumab, teriflunomide in multiple sclerosis (MS), sponsored by Novartis. Started Feb 2017; status: active, not recruiting.
02
Drugs
ofatumumabteriflunomide
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON47697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47697.